^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    MSK-ACCESS

    Company:
    Memorial Sloan-Kettering Cancer Center
    Type:
    Laboratory Developed Test
    Related tests:
    Evidence Level:
    Resistant: C3 – Early Trials

    [IL6 elevation-Melanoma-nivolumab + ipilimumab]

    Source:
    ASCO 2023
    Test:

    MSK-ACCESS

    Title:
    Final clinical results and first translational correlates of a phase 2 trial of adaptively dosed nivolumab and ipilimumab based on early radiographic assessment in advanced melanoma (ADAPT-IT).
    Published date:
    05/25/2023
    Excerpt:
    ADAPT-IT was a multicenter, phase 2 clinical trial with a planned sample size of 60 patients with unresectable melanoma. Patients received two doses of nivo (1 mg/kg) + ipi (3 mg/kg) followed by a computed tomography scan at week 6....Higher baseline IL-6 was observed in non-responders compared to responders (p = 0.03; n = 26) and was associated with shorter PFS (HR for progression or death 1.24; 95% CI: 1.01-1.52; p = 0.04).
    DOI:
    10.1200/JCO.2023.41.16_suppl.9517
    Trial ID:
    ADAPT-IT